Status:
COMPLETED
A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia
Lead Sponsor:
Astellas Pharma Singapore Pte. Ltd.
Conditions:
Metastatic Urothelial Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Cancer in the bladder lining (urothelial cancer) can be treated in many ways. One way is to directly attack cancer cells. Enfortumab vedotin is a treatment that can do this. Another way is to help the...
Eligibility Criteria
Inclusion
- Physician sample:
- Medical oncologist or urologist (Medical oncologists only in Saudi Arabia. A minimum of 15 medical oncologists in South Korea, increased where possible, with the remaining sample consisting of urologists)
- Personally responsible for treatment and management of LA/mUC patients
- At least 50 percent of time spent in management of patients
- See a minimum of 4 LA/mUC patients per month
- Accept all survey rules and requirements
- Patient sample:
- Confirmed/physician assessed diagnosis of LA/mUC
- Patient is not currently enrolled in a clinical trial
Exclusion
- Patients currently enrolled in a clinical trial
- Patients participating in, or who have previously participated, in a clinical trial
Key Trial Info
Start Date :
August 29 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2025
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT06505746
Start Date
August 29 2024
End Date
January 31 2025
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KR00001
Seoul, South Korea